What is ArrowBiome?
ArrowBiome operates at the intersection of synthetic biology and human health, specializing in the modulation of the human microbiome. The company utilizes a patented platform designed to provide highly selective bacterial targeting, offering a sophisticated alternative to traditional broad-spectrum treatments. Their product pipeline addresses a diverse range of applications, including the management of body odor, acne, and chronic skin conditions, as well as broader gut health and antimicrobial resistance challenges. By rebalancing the microbiome through precise, science-driven interventions, ArrowBiome aims to enhance long-term patient outcomes and quality of life. The company's market position is defined by its commitment to deep-tech innovation, utilizing proprietary methodologies to solve biological imbalances that have historically been difficult to treat with conventional pharmaceutical approaches.
How much funding has ArrowBiome raised?
ArrowBiome has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2024): $1M with participation from Cocoon Capital
Key Investors in ArrowBiome
Cocoon Capital
Cocoon Capital is a Singapore-based venture capital firm that specializes in early-stage investments in Deeptech and Enterprise tech companies across Southeast Asia. The firm is dedicated to supporting founders with strategic guidance and resources, ensuring that no idea is too early to receive investment.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ArrowBiome?
With this major strategic investment, ArrowBiome is poised to scale its operational capabilities and deepen its research initiatives. The company is expected to prioritize the clinical validation of its lead candidates, moving toward regulatory milestones that will facilitate market entry. Furthermore, the capital will likely be deployed to strengthen the firm's R&D infrastructure, enabling the exploration of new therapeutic areas within the microbiome space. As ArrowBiome continues to refine its selective targeting platform, the focus will shift toward strategic partnerships and commercialization efforts, aiming to establish a dominant footprint in the global biotechnology landscape. The company's trajectory suggests a robust growth phase, characterized by continuous innovation and the pursuit of scalable, science-backed health solutions.
See full ArrowBiome company page
